Efficacy of 450-nm blue laser-mediated aminolevulinic acid photodynamic therapy for plaque psoriasis: a prospective self-controlled clinical trial.

This self-controlled prospective study evaluated the efficacy and safety of 450 nm blue laser-mediated aminolevulinic acid photodynamic therapy (ALA-BL-PDT) in 28 patients with plaque psoriasis. Participants received four treatment sessions at two-week intervals. At two weeks post-treatment, 67.9% (19/28) achieved Physician Global Assessment (PGA) scores of 0 or 1 (clear or almost clear). Treatment response correlated significantly with baseline disease severity, with higher efficacy observed in patients with body surface area (BSA) ≤ 5% (84.2%) and Psoriasis Area and Severity Index (PASI) ≤ 5 (86.7%) (both p < 0.05). Treatment-associated pain was well-tolerated and decreased significantly after the first session. The one-year recurrence rate among responders was 47.4% (9/19). These preliminary results suggest ALA-BL-PDT may be effective and well-tolerated treatment for mild-to-moderate plaque psoriasis, though larger randomized controlled trials are needed for validation.